Fig. 3

Inhibition of PGD₂ suppressed microglial activation and prevented the neurodegeneration in the GPR120 KO mice. WT and GPR120 KO mice were administered indomethacin (IND) for 11 weeks. PGD₂ contents in the hippocampus (A). The protein level determined by western blot analysis (B). The level of H-PGDS (C) and Iba-1 (D) protein in the hippocampus. Immunofluorescence staining of Iba-1 (E) and Iba-1-positive cell counts in the CA3 (F) and hippocampus (G). Scale bar = 50 μm. The level of DCX protein in the hippocampus (H). The immunofluorescence of DCX (I) and DCX-positive cell counts in the dentate gyrus (J). Scale bar = 80 μm. The level of SOD2 mRNA (K) and protein (L) expression in the hippocampus. Hippocampal (M) and cortical (N) volume of WT and GPR120 KO mice. The level of synaptophysin (Syn) (O) and PSD95 (P) protein in the hippocampus. Data are mean ± SEM, n = 5 per group. Statistical analysis was performed using two-way ANOVA followed by post-hoc Tukey test (*p < 0.05; **p < 0.01; ***p < 0.001 vs. WT control, ^#p < 0.05; ^##p < 0.01; ^###p < 0.001 vs. GPR120 KO control)